Diagnexia, a provider of a remote diagnostic and consulting service platform that connects laboratories to an international network of subspecialty pathologists who can provide their expertise on clinical cases, announced an additional €3.9 million in funding, bringing its Series B round tally to €14.4 million.
Seroba Life Sciences led the additional investment round with participation from the company’s existing investors.
Commenting on the funding news announcement, Donal O’Shea, CEO of Deciphex, said: “This additional investment will allow us to continue to grow and innovate, solidifying our position as a leader in the field of pathology. We are committed to helping pathologists deliver the best possible care to patients through the use of cutting-edge technology.”
According to the company’s website, its diagnostics as a service platform, Diagnexia is a digital, subspeciality-led, remote diagnostic & consult service. The platform connects laboratories to an international network of subspecialty pathologists who can provide their expertise on clinical cases while vastly reducing turnaround times and ensuring the delivery of the highest quality of patient care. The company’s platform has already been adopted by research organizations and pharmaceutical companies around the world.
Investors
Seroba is a European life sciences venture capital firm based in Dublin and Paris. The firm has previously invested in Endotronix, a developer of cardiac monitoring solutions. Jennifer McMahon, a partner at Seroba, said: “Deciphex is at the forefront of the digital pathology and AI revolution. We were impressed by the Team’s ability to develop solutions for both clinical and preclinical pathology. As life science investors, we believe Deciphex can transform the field, benefiting patients worldwide.”
Digital pathology startups
According to our database, approximately $4 billion has been invested in digital pathology startups to date. More recently, PictorLabs, a digital pathology company developing an AI-powered virtual staining platform to revolutionize histopathology and accelerate clinical research to improve patient outcomes, raised $15.2 million in funding led by M Ventures, SCC Soft Computer, and Koç Holding. In another deal, Ibex Medical Analytics, a provider of AI-powered cancer diagnostic solutions for pathologists, raised $10 million in debt funding led by Kreos Capital, a growth debt capital provider.
